All News

I am more optimistic that we will find a way to treat those who truly need to be treated and follow those unlikely to die from their disease.

In this article, James M. Hotaling, MD, MS, outlines the elements that comprise a cost-effective workup of the infertile male patient.

Latest news, updates, and highlights right from AUA 2015

A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.

Placement of a nerve “wrap” around the neurovascular bundle during nerve-sparing robot-assisted radical prostatectomy appears to accelerate the early restoration of continence and potency following surgery, a recently published study has shown.

Other products featured include a digital card enabling mobile payment functionality, an imaging method for bladder biopsy, a surgical plume evacuation pencil, a video to help prepare patients for surgery, and more.

Listen to the interview of Dr. Neil Baum share his top five places to eat and attractions you won't want to miss out on while attending the 2015 AUA annual meeting.

Two case studies of stereotactic ablative radiation therapy yielded survival times comparable to those seen with surgical treatment.

Legislation that ends the sustainable growth rate (SGR) formula was hailed by leading urology groups as a historic, watershed event.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

Although significant time is spent developing methods or strategies that come close to that “perfect investment," none is as popular or compelling as modern portfolio theory.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.

The findings could help clinicians differentiate between slow-growing and aggressive tumors

The FDA has granted clearance to a hydrogel spacer for prostate cancer patients undergoing radiotherapy.

Caroline Rhea and Dr. Mueller speak about the steps Doctors can take to help OAB patients, from recognizing the various symptoms and behaviors of a potential OAB patient to the treatment options available for different types of OAB.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Whereas best practice policy states that antimicrobial prophylaxis for urologic procedures should be discontinued within 24 hours, extended regimens are common among patients undergoing surgery for urologic cancer and putting them at risk for hospital-acquired Clostridium difficile colitis, say researchers from the University of Washington, Seattle.

Although salvage artificial urinary sphincter implantations are associated with an increased risk of recurrent erosion/infection requiring explantation, excellent long-term success rates can be attained in carefully selected patients, according to a recent study.

Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

In men who take the 5-alpha-reductase inhibitor finasteride (Propecia) for hair loss, published data on its sexual side effects are insufficient to create a safety profile of the drug, according to a recent study.

There appears to be a trend toward third-party patient financing options in the current environment.

“I’m not satisfied. We could all do a whole lot better," one urologist told Urology Times.

A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.

Urologist Gary M. Kirsh, MD, says it’s time to bid farewell to fee for service and embrace the concept of value-based compensation in medicine.

In this column, Daniel R. Shaffer of the AACU discusses the recent Urology Joint Advocacy Conference and how urology may have helped move the needle on a promising new SGR proposal.